secwatch.observer — SEC 8-K summary
======================================

Issuer:     Arcutis Biotherapeutics, Inc. (ARQT)
CIK:        0001787306
Form:       8-K
Filed at:   2023-10-19T23:59:59+00:00
Accession:  0001628280-23-034688
Event type: earnings
Sentiment:  positive
Materiality: 0.75
Item codes: 2.02, 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Arcutis pre-announces Q3 revenue of $38.1M; ZORYVE approved for pediatric psoriasis
--------------------------------------------------------------------------------

- Preliminary Q3 2023 total revenue of $38.1M: $8.1M net product revenue (ZORYVE) and $30M other revenue from Huadong Medicine license.
- Cash, equivalents, and marketable securities of $228.1M as of Sep 30, 2023.
- FDA approved ZORYVE (roflumilast) cream 0.3% for plaque psoriasis in children ages 6-11, including intertriginous areas.
- Positive topline data from INTEGUMENT-PED and INTEGUMENT-OLE trials for atopic dermatitis in pediatric patients.
- Company implemented headcount reductions to align with pipeline reprioritization and improve financial flexibility.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1787306/000162828023034688/0001628280-23-034688-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1787306/000162828023034688/arqt-20231019.htm
  HTML page:      https://secwatch.observer/filing/0001628280-23-034688

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer